3DBio Therapeutics
Develops 3D-bioprinting and materials technologies for regenerative medicine, precision manufacturing patient-specific living tissues and implants.
- CEO / Founder
- Per Hellsund
- Stage
- Active
- Total Funding
- $40M
- Latest Round
- Series B - $20M - June 2020
- Key Investors
- Alexandria Venture Investments; Barer & Son Capital; BlueSeed Ventures; Western Technology Investment; Rapha Capital Management
Technology & Products
Key Products
3D-bioprinted living tissue implants for therapeutic applications, including foundational work on ear implants and participation in ARPA-H PRINT program for kidney bioprinting.
Technological Advantage
Claimed: Ability to bioprint living tissues with cells meeting cGMP/FDA standards. Verified: First human implant of a 3D-bioprinted ear (2022).
Differentiation
Value Proposition
Provides patient-specific living tissue implants using proprietary bioprinting and bio-ink that meet FDA cGMP standards for therapeutic use, demonstrated by the AuriNovo ear implant.
How They Differentiate
Clinical-stage focus on patient-specific living tissue implants with a demonstrated human milestone (AuriNovo) and proprietary cGMP-compliant bioprinting platform.
Market & Competition
Target Customers
Patients with congenital deformities (e.g., microtia) and regenerative medicine needs.
Industry Verticals
Regenerative medicine; Biologics
Competitors
JoMoCo, Cybrexa Therapeutics
Growth & Milestones
Growth Metrics
Revenue $618k (2025); <$5M overall.
Major Milestones
Founded 2014; 8+ years to commercial tech development; First 3D-bioprinted ear implant in human (2022); AuriNovo clinical program advancing
Notable Customers
Microtia-Congenital Ear Deformity Institute (clinical trial site)